Replies to post #77034 on Biotech Values

[DewDiligence]

AGN: Latisse did well at $12.3M for Q1.

Yes, it did., especially when you consider that Latisse was on the market for only 2/3 of the quarter and little or none of this amount was wholesaler stocking insofar as AGN distributes Latisse directly to physicians’ offices.

David Pyott, CEO, said on today’s CC that he expects Latisse to be a bigger-selling drug in due course than Botox Cosmetic, which is the term AGN uses to refer to Botox sales for cosmetic indications. In other words, Pyott expects peak Latisse sales of at least $500M, which is consistent with someone else’s forecast (#msg-34424441):

I think Latisse will easily outsell Lumigan, which does about $500M annually, and end up being a substantial product for AGN.

:- )